CN101340919B - 治疗艰难梭菌相关的腹泻的方法 - Google Patents

治疗艰难梭菌相关的腹泻的方法 Download PDF

Info

Publication number
CN101340919B
CN101340919B CN2006800479861A CN200680047986A CN101340919B CN 101340919 B CN101340919 B CN 101340919B CN 2006800479861 A CN2006800479861 A CN 2006800479861A CN 200680047986 A CN200680047986 A CN 200680047986A CN 101340919 B CN101340919 B CN 101340919B
Authority
CN
China
Prior art keywords
compound
formula
mcc
mixture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800479861A
Other languages
English (en)
Chinese (zh)
Other versions
CN101340919A (zh
Inventor
帕梅拉·希耶斯
徐润庆
斯达·路易丝·米勒-香格勒
罗伯特·布雷恩·沃尔士
法拉·巴巴汉
崔宇亨
亚历克斯·罗梅罗
舍伍德·戈尔巴奇
托马斯·约翰·路易
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hao Ding Biotech Co ltd
Optimer Pharmaceuticals LLC
Original Assignee
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals LLC filed Critical Optimer Pharmaceuticals LLC
Publication of CN101340919A publication Critical patent/CN101340919A/zh
Application granted granted Critical
Publication of CN101340919B publication Critical patent/CN101340919B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2006800479861A 2005-10-21 2006-10-23 治疗艰难梭菌相关的腹泻的方法 Expired - Fee Related CN101340919B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US60/729,135 2005-10-21
US74964105P 2005-12-12 2005-12-12
US60/749,641 2005-12-12
PCT/US2006/041436 WO2007048059A2 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011103037682A Division CN102503994A (zh) 2005-10-21 2006-10-23 治疗艰难梭菌相关的腹泻的方法

Publications (2)

Publication Number Publication Date
CN101340919A CN101340919A (zh) 2009-01-07
CN101340919B true CN101340919B (zh) 2011-12-07

Family

ID=37963388

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800479861A Expired - Fee Related CN101340919B (zh) 2005-10-21 2006-10-23 治疗艰难梭菌相关的腹泻的方法
CN2011103037682A Pending CN102503994A (zh) 2005-10-21 2006-10-23 治疗艰难梭菌相关的腹泻的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011103037682A Pending CN102503994A (zh) 2005-10-21 2006-10-23 治疗艰难梭菌相关的腹泻的方法

Country Status (7)

Country Link
EP (1) EP1940417A4 (enExample)
JP (1) JP2009512691A (enExample)
KR (1) KR101399621B1 (enExample)
CN (2) CN101340919B (enExample)
AU (1) AU2006304868B2 (enExample)
CA (1) CA2626698C (enExample)
WO (1) WO2007048059A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
EP4242295B1 (en) * 2018-06-07 2024-08-28 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2004014295A2 (en) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
TR201902533T4 (tr) * 2004-05-14 2019-03-21 Merck Sharp & Dohme Antibiyotiklerin kullanımı ile bağdaştırılan hastalıkların tedavisi.
BRPI0519890A2 (pt) * 2005-01-31 2009-03-31 Optimer Pharmaceuticals Inc macrociclos de 18 elementos e seus análogos

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B.cavalleri ,A. Arnone,E.Di Modugno,etal.structure and biological activity of lipiarmycin B.the journal of antibiotics.1988,41(3),308-315.
B.cavalleri,A. Arnone,E.Di Modugno,etal.structure and biological activity of lipiarmycin B.the journal of antibiotics.1988,41(3),308-315. *
SWANSON,R,N.etal.in vitro and in vivo evaluation of tiacumicins B and C against clostridium difficile.Antimicrobial Agents and Chemotherapy.1991,35(6),Page1108-1111. *

Also Published As

Publication number Publication date
CA2626698A1 (en) 2007-04-26
CA2626698C (en) 2015-12-01
WO2007048059A3 (en) 2007-05-31
EP1940417A4 (en) 2010-07-07
CN101340919A (zh) 2009-01-07
EP1940417A2 (en) 2008-07-09
CN102503994A (zh) 2012-06-20
KR101399621B1 (ko) 2014-06-18
HK1126410A1 (en) 2009-09-04
JP2009512691A (ja) 2009-03-26
KR20080064177A (ko) 2008-07-08
WO2007048059A2 (en) 2007-04-26
AU2006304868A1 (en) 2007-04-26
AU2006304868B2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
Nguyen et al. The lung mycobiome: an emerging field of the human respiratory microbiome
Farooq et al. Discovery of a secalonic acid derivative from Aspergillus aculeatus, an endophyte of Rosa damascena Mill., triggers apoptosis in MDA-MB-231 triple negative breast cancer cells
Martins et al. Plants used in folk medicine: The potential of their hydromethanolic extracts against Candida species
US20140107054A1 (en) Method of treating clostridium difficile-associated diarrhea
CN105753936B (zh) 一种Rakicidins类化合物Rakicidin B1及其制备方法
CN105709205B (zh) Rakicidins类化合物用于抗临床致病厌氧菌的用途
CN101340919B (zh) 治疗艰难梭菌相关的腹泻的方法
Wang et al. Polyketide glycosides from Bionectria ochroleuca inhibit Candida albicans biofilm formation
Kamble et al. Identification of α-amylase inhibitory compounds from leaves of Careya arborea Roxb. and in silico docking studies
Tian et al. Supramolecular discrimination and diagnosis-guided treatment of intracellular bacteria
Car et al. Mannosylated N‐aryl substituted 3‐hydroxypyridine‐4‐ones: Synthesis, hemagglutination inhibitory properties, and molecular modeling
Haupenthal et al. Target repurposing unravels avermectins and derivatives as novel antibiotics inhibiting energy‐coupling factor transporters (ECFTs)
Ravi et al. Antidiabetic and Antioxidant Potential of GancidinW from VITALK03
Potapenko et al. Antimicrobial and anticancer activity of Streptomyces ambofaciens (Myt 8) and S. globisporus ONU 1019 (Myt 11) secondary metabolites isolated from the Odesa Bay, the Black Sea: An in vitro study
Singh et al. Nocathiacin, thiazomycin, and polar analogs are highly effective agents against toxigenic clostridioides difficile
CN109678917A (zh) 艾美克勒霉素及其制备方法和应用
Bernabe et al. Insoluble polysaccharides produced in plant cell cultures protect from Clostridioides difficile colitis
Handayani et al. Holothurin compound from sea cucumber (Holothuria sp.) as antifungal alternative against Candida infections
Agrawal et al. Antioxidant and antibacterial evaluation of leaf extracts of Prunus cerasoides Buch.-Ham. ex D. Don; An In Vitro and In Silico study
Jaber Metabolomic profiling of antibiofilm compounds from fungal endophytes derived from Scottish seaweeds
Zhan et al. Structure characterization and repair of UVB-induced skin inflammation of rhamnomannan derived from Roseomonas mucosa DL-1
Khadagwanshi et al. Effect of Phaseolus vulgaris on E. coli induced peritonitis and bacteraemia in mice.
HK1126410B (en) Method of treating clostridium difficile-associated diarrhea
Wan et al. Biliverdin targeting TcdB-DRBD inhibits Clostridioides difficile virulence and restores gut microbiota in Mongolian gerbils (Meriones unguiculatus)
Tauber et al. In vitro inhibitory evaluation of novel amine and amide compounds against the post-translational modifier enzyme, ARTD8.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126410

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1126410

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: HAODING BIOTECHCX INC.

Free format text: FORMER NAME: OPTIMER PHARMACEUTICALS INC.

CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Optimer Pharmaceuticals Inc.

Address before: California, USA

Patentee before: Optimer Pharmaceuticals, Inc.

C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: Hayden Avenue, Lexington, Massachusetts, 65, 02421

Patentee after: Optimer Pharmaceuticals Inc.

Address before: California, USA

Patentee before: Optimer Pharmaceuticals Inc.

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Hayden Avenue, Lexington, Massachusetts, US No. 65 02421

Patentee after: Hao Ding biotech Co.,Ltd.

Address before: Hayden Avenue, Lexington, Massachusetts, US No. 65 02421

Patentee before: Optimer Pharmaceuticals Inc.

TR01 Transfer of patent right

Effective date of registration: 20151218

Address after: New jersey, USA

Patentee after: Optimer Biotechnology Inc.

Address before: Hayden Avenue, Lexington, Massachusetts, US No. 65 02421

Patentee before: Hao Ding biotech Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111207

Termination date: 20161023